AS Latvijas Juras medicinas centrs (RSE:LJM1R)

RSE:LJM1R Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	10.19	9.85	9.7	9.36	7.08
Revenue Growth (YoY)	3.42%	1.54%	3.60%	32.24%	-2.62%
Cost of Revenue	9.88	9.08	8.53	7.77	6.18
Gross Profit	0.31	0.77	1.17	1.6	0.9
Selling, General & Admin	0.66	0.67	0.71	0.58	0.56
Other Operating Expenses	-0.53	0.17	-0.17	0.14	0.07
Operating Expenses	0.13	0.84	0.54	0.72	0.63
Operating Income	0.18	-0.07	0.63	0.88	0.27
EBT Excluding Unusual Items	0.18	-0.07	0.63	0.88	0.27
Asset Writedown	-	-0.55	-	-	-
Pretax Income	0.18	-0.62	0.63	0.88	0.27
Income Tax Expense	-	0	0	0	0
Earnings From Continuing Operations	0.18	-0.62	0.63	0.88	0.27
Net Income	0.18	-0.62	0.63	0.88	0.27
Net Income to Common	0.18	-0.62	0.63	0.88	0.27
Net Income Growth	-	-	-28.92%	221.79%	66.64%
Shares Outstanding (Basic)	1	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1	1
EPS (Basic)	0.22	-0.78	0.78	1.10	0.34
EPS (Diluted)	0.22	-0.78	0.78	1.10	0.34
EPS Growth	-	-	-28.92%	221.79%	66.64%
Free Cash Flow	0.19	-0.57	0.46	-0.69	0.22
Free Cash Flow Per Share	0.24	-0.71	0.58	-0.86	0.27
Dividend Per Share	-	-	-	0.200	0.070
Dividend Growth	-	-	-	185.71%	-
Gross Margin	3.05%	7.83%	12.05%	17.07%	12.78%
Operating Margin	1.75%	-0.74%	6.46%	9.41%	3.88%
Profit Margin	1.75%	-6.34%	6.45%	9.40%	3.86%
Free Cash Flow Margin	1.86%	-5.75%	4.78%	-7.39%	3.07%
EBITDA	0.79	0.48	1.05	1.17	0.51
EBITDA Margin	7.79%	4.86%	10.87%	12.47%	7.19%
D&A For EBITDA	0.62	0.55	0.43	0.29	0.23
EBIT	0.18	-0.07	0.63	0.88	0.27
EBIT Margin	1.75%	-0.74%	6.46%	9.41%	3.88%
Effective Tax Rate	-	-	0.10%	0.07%	0.39%
Advertising Expenses	-	0.02	0.01	0	0

Source: S&P Capital IQ. Standard template. Financial Sources.